Basilea Pharmaceutica

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Basilea Pharmaceutica AG
Public (SIXBSLN)
Industry Pharmaceuticals
Founded 2000
Headquarters Basel, Switzerland
Key people
Anthony Man (CEO)
Number of employees
196
Website basilea.com

Basilea Pharmaceutica Ltd. is a Switzerland-based biopharmaceutical company that was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. Basilea is engaged in the development of antibacterial and antifungal agents to combat drug resistance.

The company is based in Basel, Switzerland. It has subsidiaries in France (Basilea Pharmaceuticals SAS), Germany (Basilea Pharmaceuticals GmbH), Denmark (Basilea Pharmaceuticals A/S), the People's Republic of China (Basilea Pharmaceutica China Ltd), Spain (Basilea Pharmaceuticals Iberia SL), the United Kingdom (Basilea Pharmaceuticals Ltd.), and the United States of America (Basilea Pharmaceuticals Inc.).[1] According to stock filings, it had 196 employees as of June 2007.[2]

Basilea is marketing Toctino (alitretinoin), for the treatment of severe chronic hand eczema, in Denmark, France, Germany, Switzerland and the United Kingdom. The drug is approved in 14 additional European countries as well as in Canada and has been recommended for approval in eight further European countries. Ceftobiprole is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus being developed in cooperation with Johnson & Johnson was approved in Europe in October 2013.[3] Isavuconazole, a broad-spectrum triazole antifungal drug in Phase III clinical development [4] has won orphan drug status in the United States.[3]

References[edit]

See also[edit]